Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Role of university hospital doctors specialized in internal medicine in health professions training and institutions in France: Survey of the National College of Teachers of Internal Medicine (CEMI)].
Rauzy O, Bouillet L, Chevalier K, Cohen-Aubart F, Delacroix I, Hanslik T, Kaplanski G, Lazaro E, Le Moigne E, Pottier P, Riviere E, Mouthon L. Rauzy O, et al. Rev Med Interne. 2024 Nov;45(11):678-686. doi: 10.1016/j.revmed.2024.07.003. Epub 2024 Aug 13. Rev Med Interne. 2024. PMID: 39142919 French.
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial.
Zeidan AM, Ando K, Rauzy O, Turgut M, Wang MC, Cairoli R, Hou HA, Kwong YL, Arnan M, Meers S, Pullarkat V, Santini V, Malek K, Kiertsman F, Niolat J, Ramos PM, Menssen HD, Fenaux P, Miyazaki Y, Platzbecker U. Zeidan AM, et al. Among authors: rauzy o. Lancet Haematol. 2024 Jan;11(1):e38-e50. doi: 10.1016/S2352-3026(23)00333-2. Epub 2023 Dec 5. Lancet Haematol. 2024. PMID: 38065203 Clinical Trial.
[Messages from the estates general on French internal medicine].
Sève P, Morlat P, Ranque B, Lavigne C, Bourgarit A, Rauzy O, Godeau B, Mouthon L. Sève P, et al. Among authors: rauzy o. Rev Med Interne. 2024 Feb;45(2):69-78. doi: 10.1016/j.revmed.2024.01.010. Epub 2024 Jan 30. Rev Med Interne. 2024. PMID: 38290857 French.
Serious infections in patients with VEXAS syndrome: data from the French VEXAS registry.
de Valence B, Delaune M, Nguyen Y, Jachiet V, Heiblig M, Jean A, Riescher Tuczkiewicz S, Henneton P, Guilpain P, Schleinitz N, Le Guenno G, Lobbes H, Lacombe V, Ardois S, Lazaro E, Langlois V, Outh R, Vinit J, Martellosio JP, Decker P, Moulinet T, Dieudonné Y, Bigot A, Terriou L, Vlakos A, de Maleprade B, Denis G, Broner J, Kostine M, Humbert S, Lifermann F, Samson M, Pechuzal S, Aouba A, Kosmider O, Dion J, Grosleron S, Bourguiba R, Terrier B, Georgin-Lavialle S, Fain O, Mekinian A, Morgand M, Comont T, Hadjadj J; French VEXAS Group. de Valence B, et al. Ann Rheum Dis. 2024 Feb 15;83(3):372-381. doi: 10.1136/ard-2023-224819. Ann Rheum Dis. 2024. PMID: 38071510
Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX.
Hadjadj J, Nguyen Y, Mouloudj D, Bourguiba R, Heiblig M, Aloui H, McAvoy C, Lacombe V, Ardois S, Campochiaro C, Maria A, Coustal C, Comont T, Lazaro E, Lifermann F, Le Guenno G, Lobbes H, Grobost V, Outh R, Campagne J, Dor-Etienne A, Garnier A, Jamilloux Y, Dossier A, Samson M, Audia S, Nicolas B, Mathian A, de Maleprade B, De Sainte-Marie B, Faucher B, Bouaziz JD, Broner J, Dumain C, Antoine C, Carpentier B, Castel B, Lartigau-Roussin C, Crickx E, Volle G, Fayard D, Decker P, Moulinet T, Dumont A, Nguyen A, Aouba A, Martellosio JP, Levavasseur M, Puigrenier S, Antoine P, Giraud JT, Hermine O, Lacout C, Martis N, Karam JD, Chasset F, Arnaud L, Marianetti P, Deligny C, Chazal T, Woaye-Hune P, Roux-Sauvat M, Meyer A, Sujobert P, Hirsch P, Abisror N, Fenaux P, Kosmider O, Jachiet V, Fain O, Terrier B, Mekinian A, Georgin-Lavialle S; FRENVEX. Hadjadj J, et al. Ann Rheum Dis. 2024 Sep 30;83(10):1358-1367. doi: 10.1136/ard-2024-225640. Ann Rheum Dis. 2024. PMID: 38777378
Loss of hematopoietic progenitors heterogeneity is an adverse prognostic factor in lower-risk myelodysplastic neoplasms.
Dussiau C, Comont T, Knosp C, Vergnolle I, Bravetti C, Canali A, Houvert A, Largeaud L, Daveaux C, Zaroili L, Friedrich C, Boussaid I, Zalmai L, Almire C, Rauzy O, Willems L, Birsen R, Bouscary D, Fontenay M, Kosmider O, Chapuis N, Vergez F. Dussiau C, et al. Among authors: rauzy o. Leukemia. 2024 May;38(5):1131-1142. doi: 10.1038/s41375-024-02234-6. Epub 2024 Apr 4. Leukemia. 2024. PMID: 38575672 Free PMC article.
29 results